Share This

PR Newswire Asia's news > Biotechnology

 |   Title only   |   Print    Next page > 
     
Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics
PHILADELPHIA , May 2, 2025 /PRNewswire/ -- Darnatein , a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), a biotechnology company advancing design-augmented biologics, announced today that it will ...
2025-05-02T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
How latest genetic data on fertility may be an indicator of chronic disease onset and longevity
SINGAPORE , May 2, 2025 /PRNewswire/ -- Latest population studies have cast new light on genetic influences on women's reproductive lifespans and possible markers for the onset of chronic diseases. ...
2025-05-02T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
HistoIndex Secures SGD9 Million Investment to Drive Next Phase of Expansion
SINGAPORE , May 2, 2025 /PRNewswire/ -- HistoIndex, known for its groundbreaking biophotonic Second Harmonic Generation (SHG) technology and a pioneering leader in Artificial Intelligence (AI) digital ...
2025-05-02T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
A Pivotal Phase II/III Clinical Study of Anti-HER2 Bispecific Antibody KN026 Have Met the Primary Endpoint of PFS at Interim Analysis
SUZHOU, China , May 1, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that a phase II/III ...
2025-05-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial
SEOUL, South Korea , May 1, 2025 /PRNewswire/ -- S&E bio Co., Ltd. , a biotechnology company specializing in exosomal microRNA-based therapies, has received approval from Korea's Ministry of Food ...
2025-05-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
JediCare Medical has announced successful completion of its first-in-human feasibility study of the world's first-of-its-kind Pulmonary Nodule Percutaneous Sphere Resection
SHANGHAI , April 30, 2025 /PRNewswire/ -- JediCare Medical Technology Co., Ltd. a Shanghai, China based company ("the Company"), jointly with West China Hospital of Sichuan University, ...
2025-04-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
ZEISS unveils AI-powered Research Data Platform; collaboration with Boehringer Ingelheim champions the future of personalized eye care
Showcasing the future of ophthalmic research at ARVO 2025: ...
2025-04-30T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical Equipment 
Mabwell Releases 6 Study Results of Innovative Drugs and Platforms at the 2025 AACR Annual Meeting
SHANGHAI , April 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented 6 study results of innovative drugs and platforms in ...
2025-04-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Genocury Biotech Annouces Groundbreaking Advance in Relapsed/Refractory DLBCL Through Pioneering In Vivo CD19 CAR-T Therapy
Genocury launched the in vivo CD19 CAR-T therapy to reach the clinical stage, demonstrating exceptional safety, efficiency and durability. ...
2025-04-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Alphamab Oncology Presented Preclinical Data on Two Novel Bispecific ADCs at the 2025 AACR Annual Meeting
SUZHOU, China , April 30, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 ...
2025-04-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
  Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.